TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Background: The phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback